Share it
Transcatheter aortic valve replacement has dominated the structural heart world in recent years, with the market currently valued at about $5 billion and the procedure becoming the primary form of aortic valve replacement in the U.S.
In 2021 and beyond, industry is setting its sights on new heart valve opportunities that could grow to be multiples of the TAVR market: transcatheter mitral valve replacement and repair.
Often in the shadow of the aortic market, mitral has a larger potential patient population, and companies with successful structural heart businesses like Abbott Laboratories and Edwards Lifesciences have secured leading positions in the market as it begins to take off.